Revenio Group Corporation, Stock Exchange Release, May 4, 2020 at 9.00 EET
JOUNI TOIJALA, REVENIO'S NEW CEO, WILL TAKE DUTY ON MAY 18, 2020
Appointed in March, Revenio's new CEO DI, MBA Jouni Toijala, (b. 1968) will take up his position on May 18, 2020. The appointment was published as a Stock Exchange Release on March 31, 2020.
"We will continue to work with Revenio's employees, management team and Board of Directors to build profitable growth further. Revenio plays an important role as a pioneer in eye diagnostic solutions to improve people's quality of life, which I find an inspiring mission. I am happy and proud that I get with my team of top professionals in the industry to develop the Group towards the next growth phase, "commented Jouni Toijala.
Prior to the position of the CEO of Revenio, Jouni Toijala has been the CEO of Innokas Medical Oy, a provider of health technology contract design and manufacturing services, the CEO of Symbio Finland Oy, a software company specializing in digital services and products and he also has held several international management positions in France and in the UK, with Nokia Group and Meridea Financial Software UK Ltd.
Timo Hildén, long-term CEO of Revenio and Icare Finland, is supporting Jouni in taking on his role to ensure a smooth transition.
In addition to the existing elements related to the remuneration of the CEO, the company has committed in the CEO agreement that the CEO is entitled to a restricted share-based incentive plan if certain conditions are met. According to this Jouni Toijala would be entitled to receive a total of 3,000 company shares during 2021-2023.
Revenio Group Oyj
Board of Directors
Further information:
Chairman of the Board
Pekka Rönkä, puh. +358 40 826 4356
pekka.ronka@revenio.fi
DISTRIBUTION:
Nasdaq Helsinki Oy
Financial Supervisory Authority (FIN-FSA)
Principal media
www.revenio.fi
The Revenio Group in brief
Revenio, a health technology group operating in the international markets, is one of the global leaders in ophthalmic appliances.
The Revenio Group consists of Icare Finland Oy, Icare USA Inc., Revenio Italy S.R.L, CenterVue SpA, CenterVue Inc, Revenio Research Oy and Oscare Medical Oy.
The common denominators of Revenio's business operations include patient-oriented screening, follow-up and the global need to make cost savings through preventive health care. Revenio seeks vigorous growth in health technology. Revenio aims to develop even more efficient and easily adopted methods for the early-stage detection of diseases with significance for public health. The aim is to improve the quality of life through health technology solutions which enable more effective diagnostics. Revenio Group's focus is on the early detection of glaucoma, diabetic retinopathy and macular degeneration, and the monitoring of these during the treatment process. Revenio Research concentrates on the commercialization of systems supporting the diagnosis of and treatment planning for skin cancer and asthma.
In 2019, Revenio Group's net sales totaled EUR 49.5 million, with its net operating profit standing at 25.5%. Revenio Group Corporation is listed on Nasdaq Helsinki.